OPAN-OTOL-MSOIA-BGMisms: Gliptins and Glitazones Aren't Associated with Adverse Cardiovascular Outcomes in Type 2 Diabetics Patients who used these drugs plus metformin had significantly lower risks for heart failure, CV disease, and all-cause death

Friday, 26 August 2016

Gliptins and Glitazones Aren't Associated with Adverse Cardiovascular Outcomes in Type 2 Diabetics Patients who used these drugs plus metformin had significantly lower risks for heart failure, CV disease, and all-cause death

Gliptins and Glitazones Aren't Associated with Adverse Cardiovascular Outcomes in Type 2 Diabetics

Patients who used these drugs plus metformin had significantly lower risks for heart failure, CV disease, and all-cause death

No comments:

Subscribe to: Post Comments (Atom)